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Iron deficiency and subsequent iron deficiency anaemia (IDA) are the most prevalent nutritional 
disorders worldwide (Zimmermann and Hurrell, 2011). The World Health Organisation (WHO) recently 
ranked iron deficiency as seventh in a list of top ten global preventable risks for death, disease and 
disability (Hurrell et al. 2004). Current strategies to counter iron deficiency include food iron 
fortification and iron supplementation (Zimmermann and Hurrell, 2007). Iron supplements are also 
administered prophylactically to pregnant women and low-birth weight infants. Both these 
interventions are heavily dependent on utilising ferrous iron based products. The iron salt ferrous 
sulphate (FeSO4), first used as an iron supplement in the 19th century, is the most commonly used 
iron source in current use (Andrews, 1999; Crosby, 1984). Despite the development of several novel 
iron forms over the past decades ferrous sulphate remains the first choice, mainly due to its low cost 
(Martnez-Navarrete et al. 2002). Ferrous sulphate, however, is highly reactive and ferrous iron based 
supplements are known to cause adverse gastrointestinal (GI) effects on account of the unabsorbed 
free iron that accumulates in the gastric lumen and irritates the mucosa (Saha, Pandhi et al. 2007; 
Schümann et al. 2007). These lead to low patient compliance and therefore severely limit the benefits 
of iron supplementation therapy (Schümann et al. 2007).  
These issues have led to the application of microencapsulation technology for oral iron delivery, 
wherein iron is incorporated within a lipid shell. The putative advantages are protecting the core 
ingredient from interacting with the other ingredients and to prevent the free iron from coming in direct 
contact with the GI mucosa thereby reducing the possibility of side effects 
Solid lipid nanoparticles (SLN’s) were first described by Muller et al, 1995 and have recently gained 
interest for drug delivery applications. SLN’s retain the advantages of traditional liposome based 
formulations such as high absorption and biocompatibility, while overcoming issues of stability 
commonly encountered with liposomes (Souto and Müller, 2010). SLN’s have been investigated for 
parenteral drug delivery and have successfully been demonstrated to possess good pharmacokinetics 
and tissue distribution characteristics when used for drugs such as doxorubicin and tobramycin 
(Bargoni et al. 2001; Zara et al. 2002). SLN based topical formulations have also been developed for 
cosmetic applications, and some products are already being marketed commercially (Castro, et al. 
2009; Müller et al. 2002). Notably, SLN’s have been investigated for oral drug delivery and have been 
shown to exhibit good release characteristics and systemic bioavailability of the encapsulated drugs 
(Demirel  et al. 2001; Yang, et al. 1999). SLN tolerability and toxicity has also been characterised in 
vivo   (Fundarò et al. 2000; Sanna et al. 2004) as well as in vitro (Müller et al. 1997; Mussi, et al. 
2013; Nassimi, et al. 2010), and they are regarded to be generally well tolerated, owing to their 
composition from physiologically similar lipids.  
In the current study, we examined the potential of SLN’s for oral iron delivery. The aim of our study 
was to formulate SLN’s incorporating the hydrophilic molecule ferrous sulphate (FeSO4), and evaluate 
iron absorption from these in vitro using the well characterised human intestinal cell line Caco-2, with 
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intracellular ferritin formation as a marker of iron absorption (Fairweather-Tait et al. 2007). We also 
examined the influence of the mucoadhesive polysaccharide chitosan (Chi) incorporation onto the 
particles on physiochemical and iron absorption characteristics of the particles by preparing chitosan 
coated SLN’s. 
 
2. Material and methods: 
2.1 Materials 
Stearic acid and polyvinyl alcohol (PVA) were from Sigma-Aldrich (Dorset, UK). Chitosan 
hydrochloride (HCL) was purchased from Heppe Medical (Halle, Germany). Unless otherwise stated 
all chemicals and reagents used were also from Sigma-Aldrich (Dorset, UK). Caco-2 cells were 
purchased from European Collection of Cell Cultures (Catalogue no. 09042001, ECACC, Salisbury, 
UK). Cell culture media and foetal calf serum (FCS) were from Invitrogen (Loughborough, UK), and 
culture plates and flasks were from Nunc (Roskilde, Denmark). Ferritin ELISA kit (Product code S-22) 
was procured from Ramco (ATI Atlas, Chichester, UK) and protein assay kit (Product no. 23225) was 
from Pierce (Thermo Fisher Scientific, Northumberland, UK). To remove any traces of residual 
minerals all reagents were prepared using ultrapure water (MilliQ; resistivity of 18.2 MΩ cm), and 
glassware and utensils were soaked in 10% HCL and then rinsed with ultrapure water. 
 
2.2 Methods 
2.2.1 SLN preparation  
Solid lipid nanoparticles were prepared using stearic acid by double emulsion solvent evaporation 
process. The preparation was based on methods described previously, with some modifications 
(Singh et al. 2010). Briefly, the oil phase was prepared by dissolving stearic acid (100 mg) in a 10 ml 
solvent mixture of dichlormethane and methanol (1:1 v/v) and pre-warming to 60 °C in a water bath.  
Aqueous emulsifier phase (PVA 10% w/v solution) with or without the addition of ferrous sulphate 
(1%, 2% or 3% w/w total lipid) was heated to equivalent temperature. Chitosan HCL (0.1%, 0.2%, or 
0.4% w/v) was added to the aqueous phase to prepare chitosan coated SLN’s. The aqueous phase 
and the oil phase were homogenised using an IKA UltraTurrax (IKA Labortechnik, Staufen, Germany) 
overhead stirrer (21,000 rpm, 60 °C, 4 mins) to obtain the primary emulsion which was then poured 
into 20 ml PVA (1% w/v) solution and homogenised again (21,000 rpm, 60 °C, 7 mins). The resultant 
double emulsion was rotary evaporated, cooled in an ice bath for 15 minutes and then washed twice 
followed by lyophilisation. SLN samples were lyophilised for 24 h (- 40°C) using a VirTis AdVantage 
2.0 BenchTop freeze dryer (SP Industries, Ipswich, UK). This was followed by a secondary drying 
phase of 8 h (20 °C). SLN preparations were then assessed for physiochemical properties and 
optimised formulations with the most favourable characteristics were selected for comparative in vitro 
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analysis experiments (iron absorption and cytotoxicity). Composition of SLN formulations is shown in 
Table 1. 
Table 1. Composition of solid lipid nanoparticle (SLN) formulations. 





(% w/w lipid) 
Chitosan concentration 
(% w/v) 
SLN 100 - - 
SLN-FeA 100 1 - 
SLN-FeB 100 2 - 
SLN-FeC 100 4 - 
SLN-ChiA 100 - 0.1 
SLN-ChiB 100 - 0.2 
SLN-ChiC 100 - 0.4 
SLN-Fe-ChiA 100 1 0.1 
SLN-Fe-ChiB 100 1 0.2 
SLN-Fe-ChiC 100 1 0.4 
 
 
2.2.2 Determination of iron incorporation efficiency 
Iron incorporation in SLN’s was determined by particle ultrafiltration followed by quantification based 
on methods described previously (Nepal et al. 2007; Ruckmani and Sankar, 2010). Briefly, SLN 
dispersions were centrifuged at high speed (13,000 rpm, 30 minutes, 4 °C); aliquots of the 
supernatant were then withdrawn and used to measure unincorporated iron spectrophotometrically 
using a modified ferrozine assay developed in our laboratory (Zariwala et al., in press). Aliquots of test 
samples and iron standards were pipetted into microcentrifuge tubes containing HCL (0.5 M).  
Detection reagent (2 mM ferrozine) was then added further and the tubes incubated in the dark for 60 
mins. Ferrous iron binds with ferrozine to form a strongly coloured purple complex with an absorption 
maximum at 562 nm (Fish, 1988). Samples were pipette into a 96-well microplate and absorbance 
read at 562 nm using a microplate reader (VersaMax, Molecular devices, USA). Iron content in test 
samples was calculated from the standard curve generated from the iron standards. 
 Mean of three independent readings were recorded and results were expressed as means ± 
standard deviations (SD). 
Iron incorporation in SLN’s was determined according to the following equation: 
Iron incorporation efficiency (%) =  (Ti - Fi / Ti) x 100 
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Where Ti is the total iron added during formulation and Fi is the free (unincorporated) iron measured 
in supernatant. 
 
2.2.3 SLN characterisations 
 
2.2.3.1 Particle size measurements 
 
Size analysis was carried out on SLN dispersions as well as lyophilised SLN samples using the 
Malvern Zetasizer Nano ZS (Malvern Instruments, UK), carrying out three measurements on each 
sample. Results were analysed using the Fraunhofer model and presented as mean particle size ± 
SD. 
2.2.3.2 Zeta potential analysis 
Zeta potential analysis of SLN’s was carried out on dispersions diluted in MilliQ water; all 
measurements were replicated in triplicate. Electrophoretic mobility of the dispersions was then 
measured by laser doppler anemometry (Zetasizer Nano ZS, Malvern Instruments, UK).  
2.2.3.3 SLN imaging  
Drop’s of SLN dispersions were applied to a copper grid and stained with 2% phosphotungstic acid 
solution. SLN’s were then imaged using a Philips Biotwin CM120 transmission electron microscope 
(TEM; Philips Biotwin CM120, Philips Co, The Netherlands). 
 
2.2.4 Thermal analysis of SLN using differential scanning calorimetry (DSC) 
Thermal analysis of pure compounds (ferrous sulphate and stearic acid), and lyophilised SLN 
preparations was carried out using differential DSC (DSC Q2000 module, TA Instruments, LLC, USA). 
Aluminium hermetic pans containing a 50 µm pinhole were used to load the lyophilised preparations 
pans (TA Instruments, New Castle, UK) as described previously (Slager and Prozonic, 2005). A 
heating rate of 20 °C per min was employed in the 0–300 °C range under nitrogen atmosphere at a 
flow rate of 50 ml/min. 
 
2.2.5 Cytotoxicity assay 
SLN cytotoxicity was assessed using an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium 
bromide) assay (Mosmann, 1983; Silva et al. 2011). Briefly, Caco-2 cells were seeded onto 96-well 
plates at a seeding density of 3 x 104 cells/cm2 and media replenished every 48 hours. Growth media 
was then aspirated and cells incubated for 48 or 72 hours with test media comprising of phenol red 
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free Dulbecco’s Modified Eagle Medium (DMEM) supplemented with SLN’s at volumes equivalent to 
final iron concentrations of 20, 50 and 100 µM. Corresponding blank SLN formulations were added at 
equivalent volumes. Following incubation periods, cells were solubilised in dimethyl sulfoxide (DMSO) 
and the absorbance measured in a plate reader (VersaMax, Molecular devices, USA) at 550 nm 
wavelength. Cell viability was expressed as a percentage of untreated control cells (100%). 
 
2.2.6 Caco-2 cell iron absorption 
Caco-2 cells (passage no. 45 to 55) were seeded onto 6-well plates at an initial seeding density of 3 x 
104 cells/cm2. Parallel 6-well plates were also seeded similarly to be used for assessment of cell 
viability prior to the commencement of the absorption experiment and following completion. Cells 
were cultured in an incubator at 37 °C in an atmosphere of 95 % air and 5 % CO2 at constant 
humidity, replacing the medium (FCS supplemented DMEM; Dulbecco’s Modified Eagle Medium) 
every two days. Caco-2 cells differentiate to a fully matured gastrointestinal (GI) tract phenotype 14-
15 post seeding. Day 13 - cell monolayers were incubated in serum-free minimum essential media 
(MEM) for 24 hours after washing times with wash solution (140 mM NaCl, 5 mM KCl, 10 mM PIPES 
buffer, pH 6.7, 37ºC). Day 14 - Treatment media was prepared by adding SLN samples (20 µM final 
iron concentrations) to aliquots of test media (MEM, pH 5.8, buffered with 2-[N-Morpholino] 
ethanesulfonic acid 10 mM). Caco-2 cell monolayers were washed three times with wash solution and 
iron enriched treatment media was added to cell monolayers (n = 6 wells per condition). Plates were 
incubated for 2 hours at 37ºC on a rotating plate incubator (25 rpm). Test media was then aspirated 
and cells washed twice with wash solution and once with surface bound iron removal solution (wash 
solution plus 5 µm Na hydrosulphite and 1 µm bathophenanthroline disulfonate) (Glahn et al. 1995). 
Cells were then placed in a cell culture incubator for 24 h after which they were subjected to lysis (50 
mM NaOH supplemented with 1 µg/ml protease inhibitor cocktail (Sigma-Aldrich product # P8340) 
followed by harvesting (using a cell scraper) and collecting the lysate into microcentrifuge tubes. 
 
2.2.6.1 Iron absorption analysis 
Iron absorption was determined by measuring total ferritin protein concentration in cell lysates using a 
spectrophotometric ELISA kit as described previously (Zariwala et al., in press; Thompson et al. 
2010). BCA protein assay kit (Thermo Fisher Scientific (Northumberland, UK) was used to determine 
total protein content of Caco-2 cell lysates. Samples were assayed in duplicate following 
manufacturer’s protocol using bovine serum albumin (BSA) stock (2 mg/ml) as a standard. 
Absorbance was measured at 562 nm using a microplate reader (VersaMax, Molecular devices, 
USA). Ferritin concentration was then standardised against total protein concentration (ng ferritin/mg 




2.2.7 Statistical analysis 
For iron absorption experiments mean of six replicates was calculated for each treatment, and the 
data presented as mean ± SD. All data was analysed by ANOVA followed by Tukey's post-hoc test 
using the PRISM software package (Version 4, Graphpad Software Inc., San Diego, USA). In all 
cases results were considered significantly different if p ≤ 0.05. 
 
3. Results and Discussion 
3.1 Effect of initial iron content on SLN iron incorporation efficiency. 
A preliminary experiment was carried out to optimise initial iron concentration in the SLN formulations. 
The formulations were therefore prepared using varying iron concentrations (1%, 2% and 4% w/w 
lipid) and SLN incorporation efficiencies determined. Our results demonstrate that increasing initial 
iron concentration from 1% to 2% and 2% to 4% w/v resulted in a 29.57% (p < 0.01) and 21.12% (p < 
0.05) decrease (respectively) in iron incorporation efficiency of the lipid particles (Fig. 1). This is in 
agreement with previous studies in liposomes by Xia and Xu (2005), where an inverse relationship 
was observed between increasing iron to lipid content and liposome iron entrapment (Xia and Xu, 
2005). Factors that influence SLN drug incorporation include solubility and miscibility of the drug in the 
lipid melt, physiochemical interactions between the drug and encapsulating material, and formulation 
parameters such as homogenisation amplitude time (Mehnert and Mäder, 2001). It has been 
suggested that the strong electrolytic properties of ferrous iron might have a detrimental effect on the 
lipid vesicle wall formation (Hermida et al. 2010; Xia and Xu, 2005). High initial iron concentration may 





Fig. 1. Effect of initial iron concentration (% w/w lipid) upon solid lipid nanoparticle (SLN) iron 
incorporation efficiency. Results are expressed as mean ± SD (n =3). ** signifies p < 0.01 and * 
signifies p < 0.05. 
 
The initial amount of ferrous iron added to the SLN formulations was thus optimised at 1% w/w of the 
total lipid. A second batch of formulations was prepared with this optimised iron concentration (1% 
w/w total lipid) to investigate the effect of chitosan inclusion upon SLN iron incorporation. Chitosan-
HCL was used at concentrations of 0.1%, 0.2% and 0.4% w/v. Chitosan inclusion at 0.2% w/v 
concentration was observed to result in a statistically significant increase in SLN iron incorporation as 
compared to SLN-Fe alone (p < 0.05, Fig. 2). However, increasing chitosan concentration from 0.2% 
to 0.4% w/v did not result in a significant increase in iron incorporation efficiency (Fig.2). Inclusion of 
chitosan has been shown previously to result in increased iron loading in lipid vesicles (Hermida et al. 
2010; Xia and Xu, 2005). It has been suggested that iron forms a stable complex with the lipid 
associated chitosan, resulting in higher incorporation (Bhatia and Ravi, 2003).  
 
Fig. 2. Effect of chitosan inclusion on solid lipid nanoparticle (SLN) iron incorporation efficiency. 
Results are mean ± SD (n = 3). * Indicates significant difference from chitosan free SLN.  
 
3.2 Physiochemical properties of SLN’s  
Particle size distribution and zeta potential of SLN’s are shown in Table 1. Mean particle size of all 
SLN’s was of submicron dimensions (300.3 ± 31.75 nm to 495.1 ± 80.42 nm). Lyophilisation led to a 
moderate increase in SLN particle size. The presence of iron did not result in any significant changes 
in SLN particle size (Table 2). Chitosan inclusion however did lead to a significant increase in particle 
size as compared to chitosan free SLN formulations (Table 2).  
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Generally, an inverse relationship is observed between the emulsifier concentration and the size of 
the lipid particles (Lim and Kim, 2002). We optimised PVA emulsifier concentration at 10 % w/v, as 
this concentration, along with formulation parameters (temperature and homogenisation time) resulted 
in particles within our desired size range. Very small sized SLN’s (sub 200 nm) are favoured for drug 
delivery applications such as anti-cancer drugs and for targeted delivery across the blood brain barrier 
(BBB), where high drug penetration and retention is desirable (Chen and Liu, 2012; Kaur et al. 2008; 
Oyewumi, et al. 2004). In the case of these delivery systems, the small size of the particles is 
considered advantageous to avoid reticoendothelial clearance (Chen and Liu, 2012). However, for 
oral iron delivery our objective was to formulate iron loaded particles that follow the conventional 
mode of iron absorption; i.e. via controlled entry through the intestinal enterocytes.  
 
Table 2. Physiochemical properties of solid lipid nanoparticles (SLN). All values are mean ± SD (n = 
3).  
 











SLN 369.1 ± 43.2 604.93 ± 64.6 -10.3 ± 3.4           - 
SLN-FeA 333.7 ± 55.4 516.27 ± 67.2 -12.2 ± 1.9 70.57 ± 4.5 
SLN-FeB 300.3 ± 31.8 306.77 ± 37.8 -15.8 ± 0.2 48.48 ± 4.0 
SLN-FeC 331.3 ± 27.6 312.47 ±  4.8 -17.8 ± 1.8 53.92 ± 6.5 
SLN-ChiA 546.9 ± 66.7 651.3 ± 167.2 3.43 ± 0.2            - 
SLN-ChiB 716.7 ± 88.9 750.2 ± 87.6 3.59 ± 0.8           - 
SLN-ChiC 655.0 ± 100.1 948.0 ± 110.4 7.82 ± 0.6           - 
SLN-Fe-ChiA 554.2 ± 78.7 602.2 ± 64.8 5.55 ± 0.5 81.84 ± 8.5 
SLN-Fe-ChiB 495.1 ± 80.4 788.6 ± 250.6 6.90 ± 1.8 87.01 ± 4.2 
SLN-Fe-ChiC 690.2 ± 78.1 736.4 ± 146.9 10.7 ± 0.1 87.70 ± 5.7 
 
 
Zeta potential analysis indicates particle surface charge, and is considered predictive of formulation 
stability, particularly for emulsions and colloidal suspensions (Heurtault et al. 2003).  Stearic acid 
SLN’s had a net negative surface charge, in agreement with previous studies (Wang et al. 2012). In 
all cases, iron incorporation did not significantly alter particle surface charge, as indicated by the 
comparison of zeta potential between blank and corresponding iron loaded SLN’s. Chitosan conferred 
a net positive charge on the surface of the lipid particles, with increasing chitosan concentrations 
(from 0.1% to 0.4% w/v) leading to a corresponding increase in surface charge (Table 2.). An overall 
net positive zeta potential of the lipid particles leads to electric repulsion between the particles 
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reducing the likelihood of aggregation (Heurtault et al. 2003).  Positively charged particles are also 
known to exhibit greater cellular binding and consequent cellular uptake (Yu et al. 2012). 
SLN surface and shape characteristics were visualised by TEM (Fig. 3.). The imaging confirms the 
uniformly well formed spherical shape and structures of the SLN’s. Particles appear free from 
aggregation further confirming the stable formulation characteristics of the SLN’s.  
 
Fig. 3. Transmission electron microscopy (TEM) image of iron loaded SLN-Chi-FeB visualised at 
46,000x magnification. 
 
3.3 Thermal properties of SLN’s. 
DSC was used to analyze the thermophysical properties of SLN’s and their individual components 
(e.g. stearic acid and ferrous sulphate) to study changes which may result from particle formation and 
component interaction. Stearic acid was shown to exhibit a bifurcated peak with melting points at 
60.55 °C and 71.22 °C (Fig. 4A) indicating that the unmodified stearic acid used in this study has 
crystalline properties, in agreement with previous studies (Cavalli et al., 1997).The bifurcated peak 
may indicate the presence two crystalline polymorphic forms of which the less stable polymorph (at 
60.55 °C) disappears in the blank SLN formulations suggesting a decline in the crystallinity of stearic 
acid upon SLN formation (Fig 4A).  Ferrous sulphate showed the presence of three endorthermic 
peaks ( 76.09 °C, 106.5 °C and 124.64 °C) indicating its crystalline properties (Fig.  4B). All three 
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ferrous peaks disappeared in the diffractograms of ferrous iron loaded SLN particles (Fig 4B) 
suggesting that ferrous sulphate interacts with the SLN components during the formulation process 
and this gives rise to a SLN crystal structure that is distinct from that of individual components. 
Previous studies in SLN’s have demonstrated that during formulation the lipid components undergo 
arrangements into lamellar lattice structures, and crystalline compounds are incorporated and stored 
within these layers (Lukowski et al. 2000).Our DSC data therefore suggest that ferrous sulphate is 
successfully incorporated within the lipid matrix of the SLN’s during the formulation process and is in 





Fig. 4. Thermal analysis of solid lipid nanoparticles (SLN’s). A: DSC thermograms of stearic acid and 





SLN formulations were selected for in-depth in vitro analysis in Caco-2 cells based on the results of 
the characterisation analysis. SLN iron concentration was selected at 1% w/w lipid as this 
concentration resulted in the highest incorporation efficiency and likewise, the chitosan concentration 
was selected at 0.2% w/v as SLN formulations at this concentrations demonstrated a favourable 
balance between requisite size, charge and iron incorporation properties. Thus iron containing SLN-
FeA and SLN-Fe-ChiB and their corresponding blank SLN formulations SLN and SLN-ChiB were 
assessed in our in vitro experiments for cytotoxicity and iron uptake. 
 
3.4 SLN cytotoxicity analysis 
Although SLN formulation ingredients were carefully selected, there might be concerns regarding SLN 
effect on cell viability either upon contact with the cell membrane or following cellular entry. We 
sought to address this by carrying out SLN cytotoxicity analysis in Caco-2 cells using the well 
characterised MTT assay. Caco-2 cells were exposed to SLN formulations standardised at increasing 
iron concentrations (20, 50 and 100 µM), with corresponding iron free SLN formulations also included, 
and cytotoxicity assessed at two time points (48h and 72h). Our results demonstrate that none of the 
SLN formulations exerted any potential cytotoxic effects on Caco-2 cells at any time point (Fig 5). Cell 
viability in all cases was at least 80% of control cells (Fig. 5). Our results therefore demonstrate the 




Fig. 5. SLN cytotoxicity analysis. Caco-2 cells viability was assessed by MTT assay following 
incubation with SLN formulations for 48 and 72 h at varying iron concentrations (20 µM, 50 µM and 
100 µM), with corresponding blank SLN formulations included at equivalent volumes. Results are 




3.5 SLN iron absorption in Caco-2 cells 
Our results demonstrate significantly higher iron absorption from SLN formulations. Iron absorption 
from SLN-FeA (583.98 ± 40.83 ng/mg) was 13.42% higher than free ferrous sulphate reference 
whereas for SLN-Fe-ChiB (642.77 ± 29.37 ng/mg) it was 24.9% higher than the ferrous sulphate 
reference (p < 0.05). The chitosan coated formulation SLN-Fe-ChiB demonstrated the overall highest 
iron absorption (514.66 ± 20, p < 0.05). The high lipid content of the SLN formulations offers a 
possible explanation to account for the enhanced iron absorption profile observed from these 
formulations as compared to free iron. Lipids are known to enhance intestinal absorption of entrapped 
or co-administered drugs via several putative mechanisms, and several studies have reported lipid 
mediated enhancement of absorption and bioavailability of both lipophilic and hydrophilic drugs 
including zidovudine (Singh et al. 2010), tretinoin (Das et al. 2011) and puerarin (Luo et al. 2011). The 
inherent lipophilic nature of lipid-based systems promotes particle transport across the bimolecular 
lipid membrane of most mammalian cells such as gut enterocytes (Eldridge et al. 1990). Lipid 
particles are also known to exhibit bioadhesive properties, which allow them to adhere to the GI tract 
thereby increasing the likelihood of cellular uptake (Severino et al. 2012). Lipids might also function as 
permeability enhancers that modify the barrier function of the GI tract (Aungst, 2000). Some studies 
have suggested that lipids enhance intestinal bioavailability of drugs by attenuating efflux 
transporters, such as p-glycoprotein located on the apical intestinal mucosa (Constantinides and 
Wasan, 2007; Dintaman and Silverman, 1999). Stearic acid, a long chain fatty acid, was used as the 
lipid phase in our formulations. Stearic acid has been used extensively to prepare SLN’s for various 
drugs and bioactives (Guan et al. 2011; Yuan et al. 2007; Zhang et al. 2000). Despite being a 
saturated fatty acid it has not been shown to causes adverse changes in serum cholesterol levels 
(Grundy, 1994). Our choice of stearic acid as the lipid component was further reinforced on account of 
its United States Food and Drug Administration Generally Recognised as Safe (USFDA GRAS) status 
as a food additive (U.S. FDA Code of Federal Regulations), suggestive of a good biocompatibility 
profile (Osborn and Akoh, 2002). 
Iron absorption from SLN’s was determined by measuring Caco-2 cell ferritin formation (Zariwala et 
al., in press). Ferritin is an iron storage protein that is widely considered a marker of iron absorption 
(Andrews, 1999), and the Caco-2 ferritin model has been well characterised for in vitro iron absorption 
studies (Alvarez-Hernandez et al. 1991). Several studies have also demonstrated physiologically 
relevant iron uptake and synthesis machinery in this cell system (Fairweather-Tait et al. 2007). Caco-
2 cells are known to synthesise ferritin based on their intracellular iron levels and iron concentrations 
in their surrounding environment (Sharp, 2005). Cells were therefore cultured in iron depleted media 
for 24 h prior to experiments and then incubated with equivalent amounts of iron (20 µm) from the test 
formulations for two hours. The test iron concentration and the incubation time were based on 
previous studies that have demonstrated these parameters to be optimum for comparative iron uptake 





Fig. 6. Caco-2 cell iron absorption from test SLN formulations. Results are shown as mean ± SD (n = 
6), * indicates a significant difference between ferrous sulphate control and SLN-FeA (p < 0.05). † 
indicates significant difference between SLN-FeA and SLN-Chi-FeB (p < 0.05). 
 
 
Chitosan integration in our SLN’s led to markedly augmented Caco-2 cell iron absorption. Chitosan is 
known to function as an absorption enhancer when included in micro and nano-particle formulations, 
an effect attributed to its mucoadhesive properties that have been well described (Fonte et al. 2011). 
The apical surface of duodenal enterocytes is coated with a glycocalyx layer that possesses a net 
negative charge (Snoeck et al. 2005). Chitosan has a strong positive charge owing to the presence of 
amine groups in its structure; this leads to strong electrostatic attraction with the cell surface and 
subsequent bioadherence that is conducive to increased absorption. Other groups have also 
demonstrated similar results; Takeuchi and colleagues (2003) reported increased enterocyte uptake 
of calcitonin loaded liposomes surface coated with chitosan, while Fonte et al. (2011) recently showed 
high oral absorption from chitosan coated solid lipid particles (Fonte et al. 2011; Takeuchi et al. 2003). 
As described earlier, chitosan inclusion also led to increased iron incorporation and modification of the 
surface charge of the lipid particles. Chitosan inclusion in the SLN’s therefore leads to markedly 
higher iron absorption from SLN; an effect we attribute to its mucoadhesive and permeation 
enhancing properties that might further supplement the cellular uptake properties of the SLN vehicle. 
 
4. Conclusion 
We demonstrate, for the first time, the preparation of ferrous iron loaded SLN’s as a platform for iron 
delivery. SLN preparation was optimised for initial iron content and surface charge, and these 
parameters were demonstrated to have a profound influence on their physiochemical and in vitro iron 
absorption characteristics. Our results show Caco-2 cell iron absorption from SLN’s at levels higher 
than free ferrous sulphate. Inclusion of chitosan at an optimised concentration of 0.2% w/v imparted a 
net positive charge on the particle surface and led to a further augmentation of iron absorption from 
SLN’s. In conclusion, we have developed a lipid-based oral iron delivery system with good iron 
incorporation and physiochemical characteristics as well as high absorption properties in vitro. Iron 
16 
 
loaded SLN’s offer a versatile drug delivery system; they can be administered as nanodispersions, in 
powdered form (upon lyophilisation), and as a tableting ingredient to be added during the granulation 
process. Iron containing SLN’s thus provide an attractive delivery system for conventional oral iron 
therapy.   
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Captions for illustrations 
 
Table 1. Composition of solid lipid nanoparticle (SLN) formulations. 
Table 2. Physiochemical properties of solid lipid nanoparticles (SLN). All values are mean ± SD (n = 
3).  
Fig. 1. Effect of initial iron concentration (% w/w lipid) upon solid lipid nanoparticle (SLN) iron 
incorporation efficiency. Results are expressed as mean ± SD (n =3). ** signifies p < 0.01 and * 
signifies p < 0.05. 
Fig. 2. Effect of chitosan inclusion on solid lipid nanoparticle (SLN) iron incorporation efficiency. 
Results are mean ± SD (n = 3). * indicates significant difference from chitosan free SLN.  
Fig. 3. Transmission electron microscopy (TEM) image of iron loaded SLN-Chi-FeB visualised at 
46,000x magnification. 
Fig. 4. Thermal analysis of solid lipid nanoparticles (SLN’s). A: DSC thermograms of stearic acid and 
blank SLN. B: DSC thermogram of ferrous sulphate (FeSO4) loaded SLN formulations (SLN-FeA, 
SLN-FeB, and SLN-FeC). 
Fig. 5. SLN cytotoxicity analysis. Caco-2 cells viability was assessed by MTT assay following 
incubation with SLN formulations for 48 and 72 h at varying iron concentrations (20 µM, 50 µM and 
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100 µM), with corresponding blank SLN formulations included at equivalent volumes. Results are 
mean ± SD (n = 6). 
Fig. 6. Caco-2 cell iron absorption from test SLN formulations. Results are shown as mean ± SD (n = 
6), * indicates a significant difference between ferrous sulphate control and SLN-FeA (p < 0.05). † 
indicates significant difference between SLN-FeA and SLN-Chi-FeB (p < 0.05). 
 
